Factors Affecting the Pharmacokinetics of Pyrazinamide and Its Metabolites in Patients Coinfected with HIV and Implications for Individualized Dosing-Reference-Cited by-同舟云学术

Factors Affecting the Pharmacokinetics of Pyrazinamide and Its Metabolites in Patients Coinfected with HIV and Implications for Individualized Dosing

Published:2021-06-17 Issue:7 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Sundell Jesper¹^ORCID,Wijk Marie¹,Bienvenu Emile²,Äbelö Angela¹,Hoffmann Kurt-Jürgen¹,Ashton Michael¹

Affiliation:

1. Unit for Pharmacokinetics and Drug Metabolism, Department of Pharmacology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

2. Department of Pharmacy, School of Medicine and Pharmacy, University of Rwanda, Kigali, Rwanda

Abstract

Pyrazinamide is a first-line drug used in the treatment of tuberculosis. High exposure to pyrazinamide and its metabolites may result in hepatotoxicity, whereas low exposure to pyrazinamide has been correlated with treatment failure of first-line antitubercular therapy.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00046-21

Reference37 articles.

1. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: Effectiveness, Toxicity, and Acceptability

2. Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives

3. Current Overview of Anti-Tuberculosis Drugs: Metabolism and Toxicities

4. Optimizing the clinical pharmacology of tuberculosis medications

5. Impact of the host environment on the antitubercular action of pyrazinamide

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population Pharmacokinetic Modeling of Pyrazinamide Among Chinese Patients With Drug-Sensitive or Multidrug-Resistant Tuberculosis;Therapeutic Drug Monitoring;2024-09-06

2. Correlations among the plasma concentrations of first-line anti-tuberculosis drugs and the physiological parameters influencing concentrations;Frontiers in Pharmacology;2023-10-06

3. Is there a need to optimise pyrazinamide doses in patients with tuberculosis? A systematic review;International Journal of Antimicrobial Agents;2023-09

4. Pharmacokinetic Considerations for Optimizing Inhaled Spray-Dried Pyrazinoic Acid Formulations;Molecular Pharmaceutics;2023-08-17

5. Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis;Antimicrobial Agents and Chemotherapy;2022-07-19